Sinobiomed Inc. (OTCBB: SOBM)
will begin a Phase II clinical trial of its malaria vaccine candidate,
PfCP2.9, in Thailand in Q3 2008. Thailand is currently experiencing a
malaria epidemic, which is why the trial is sited there.
In its Phase I trial, which was completed in 2004, PfCP2.9 generated a
strong immune response with only mild side effects. In January 2008,
Sinobiomed was awarded a 9 million RMB ($1.2 million) government grant
for PfCP2.9 as part of China's 863 Program that encourages
technologically innovative products.
Two-thirds of the money will be used to underwrite the costs of the
clinical trial; the other one-third will support development of a
multistage, multivalent vaccine, based on PfCP2.9. The current form of
the vaccine targets the most deadly malaria parasite (Plasmodium
falciparum) at its most destructive stage – rapid replication in human
red blood cells. The goal of the multivalent vaccine is to improve
immunogenicity and extend the immune period.
The PcFP2.9 vaccine was developed by SMMU. Sinobiomed's China
subsidiary, Shanghai Wanxing, has exclusive rights to market the
product, if it is approved.
The Phase II trial of the malaria vaccine will be conducted by
Sinobiomed in collaboration with Mahidol University in Bangkok,
Thailand. The study site is located in Thailand's Ratchaburi Province,
approximately 200 km from Bangkok near the Myanmar border.
i On The Market - Daily Newsletter
Every trading day, be ready to attack the market instead of reacting to the market.
You will know where the key technical resistance and support levels are and what the market is likely to do next. iStock will arm you with a target list of stocks to buy and sell - right now - based on our exclusive, proprietary trading models.
Two Week FREE Trial